Synthesis of new 4-anilinoquinazoline analogues and evaluation of their EGFR inhibitor activity.
- Author:
Zheng WANG
;
Cui-Ling WANG
;
Jun-lin LI
;
Ning ZHANG
;
Yan-ni SUN
;
Zhu-lan LIU
;
Zhi-shu TANG
;
Jian-li LIU
- Publication Type:Journal Article
- MeSH:
Aniline Compounds;
pharmacology;
Antineoplastic Agents;
pharmacology;
Cell Line, Tumor;
Humans;
Inhibitory Concentration 50;
Phosphorylation;
Quinazolines;
pharmacology;
Receptor, Epidermal Growth Factor;
antagonists & inhibitors
- From:
Acta Pharmaceutica Sinica
2015;50(12):1613-1621
- CountryChina
- Language:English
-
Abstract:
Thirteen of 4-anilinoquinazoline derivatives with imine groups at position 6 of quinazoline ring were synthesized and their antitumor activities were evaluated by MTT assay and Western blotting analysis. Among these compounds, 13a-131 were reported first time. The MTT assay was carried out on three human cancer cell lines (A549, HepG2 and SMMC7721) with EGFR highly expressed. Among the tested compounds, 13i and 13j exhibited notable inhibition potency and their IC50 values on three cell lines were equivalent to or less than those of gefitinib. Compound 14, without imine group substituted, displayed excellent inhibitor potency only on A549 cell line. Compounds 14 and 13j were chosen to perform Western blotting analysis on A549. The results showed that both of the compounds could inhibit the expression level of phosphorylated EGFR remarkably. It was concluded that the inhibitor potency of compound 14 was almost equivalent to that of gefitinib and the inhibitor potency of 13j was better than that of gefitinib.
